ClinicalTrials.gg
TerminatedNCT02418754CAPELLAUpdated Oct 26, 2020Results posted

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

A Phase 2 interventional study of REGN2176-3 and Intravitreal Aflibercept Injection (IAI) in Neovascular Age-Related Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Terminated at 84 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-10-26.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
No additional efficacy seen with REGN2176-3 over aflibercept alone

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
505
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
6th of 66
505 · median 55
Started
2015
with 5 others
Phase 2
7 of 66
none open now
Registered
33rd of 66
by date
Lead sponsor
10 of 66
Regeneron Pharmaceuticals

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 6th largest by enrollment, is one of 6 that started in 2015, is one of 7 in phase 2, and was the 33rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy.

The secondary objectives of the study were the following:

  • To explore the effect of 2 dose levels of IVT REGN2176-3 on anatomical changes of CNV in participants with nAMD compared to IAI monotherapy (at week 12)
  • To evaluate if short-term treatment with REGN2176-3 followed by IAI monotherapy offered the same or additional benefit compared to continuous treatment with REGN2176-3. Also to determine if there was benefit in initiating IAI treatment prior to REGN2176-3 compared to continuous treatment with IAI.
  • To assess the safety and tolerability of IVT REGN2176-3 in participants with nAMD
03

Conditions studied

  • Neovascular Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Men or women ≥50 years of age
  2. Active subfoveal CNV secondary to AMD as evidenced by FA in the study eye, as determined by the reading center, including juxtafoveal lesions that affect the fovea
  3. BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye at the screening visit
  4. Provide signed

Key Exclusion Criteria:

  1. Any prior treatment with anti-VEGF treatment in the study eye
  2. Any prior treatment (ie, systemic or ocular treatment) with PDGF or PDGFR inhibitors
  3. Dense fibrotic scar or atrophy in the study eye involving the center of the fovea
  4. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye
  5. Prior vitrectomy in the study eye
  6. Any history of macular hole of stage 2 and above in the study eye
  7. Any intraocular or periocular surgery within 3 months of day 1 in the study eye, except lid surgery
  8. History of corneal transplant in the study eye
  9. Evidence of diabetic retinopathy or diabetic macular edema in either eye
  10. Positive serum human chorionic gonadotropin/urine pregnancy test at the screening or baseline visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
505 participants (actual)

Study arms

  • Experimental
    REGN2176-3 (1 mg: 2 mg)

    Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.

    Drug: REGN2176-3

  • Experimental
    REGN2176-3 (3 mg: 2 mg)

    Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.

    Drug: REGN2176-3

  • Experimental
    Intravitreal Aflibercept Injection (IAI) 2 mg

    IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.

    Drug: Intravitreal Aflibercept Injection (IAI)

  • Experimental
    REGN2176-3 (3 mg: 2 mg) to IAI 2 mg

    Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.

    Drug: Intravitreal Aflibercept Injection (IAI)

  • Experimental
    IAI 2 mg to REGN2176-3 (3 mg:2 mg)

    IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.

    Drug: REGN2176-3

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12

    Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT)

    CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.

    Time frame: Baseline, Week 12

  2. Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT)

    CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation.

    Time frame: Week 12

  3. Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA)

    The anatomical state of the retinal vasculature of the study eye and the fellow eye was evaluated by funduscopic examination, fundus photography and FA to evaluate the total lesion area, CNV area, classic CNV area, and fluorescein leakage. CNV area values measured in square millimeters, each disc area was equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA)

    Total Lesion Size was assessed by Fluorescein Angiography.

    Time frame: Baseline, Week 12

  5. Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)

    Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at Week 12 compared with baseline.

    Time frame: Week 12

  6. Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT)

    SHM was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT)

    CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.

    Time frame: Baseline, Week 12

07

Results

Posted Oct 26, 2020

Participant flow

The study was conducted at 82 sites in US and 11 sites in Japan. A total of 804 participants were screened. Out of 804 participants, 505 were randomized and treated.

Period 1 (Day 1 to Week 12)
Participant flow — Period 1 (Day 1 to Week 12)
MilestoneGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mgGroup 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mgGroup 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg)
Started10320020200
Completed10119620000
Not completed24200
Withdrew: Adverse event02000
Withdrew: Death10000
Withdrew: Physician decision10000
Withdrew: Withdrawal by subject02100
Withdrew: Lost to follow-up00100
Period 2 (Day 1 to Week 52/End of Study)
Participant flow — Period 2 (Day 1 to Week 52/End of Study)
MilestoneGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mgGroup 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mgGroup 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg)
Started1031061089494
Completed7064716767
Not completed3342372727
Withdrew: Adverse event37622
Withdrew: Death10000
Withdrew: Physician decision2628262124
Withdrew: Withdrawal by subject34410
Withdrew: Lost to follow-up02121
Withdrew: Other un-specified01010

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12
LettersGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg
Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 125.9 ± 1.015.7 ± 0.737.4 ± 0.72
Statistical analysis
  • Group 1: REGN2176-3 (1 mg:2 mg) vs Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg · ANCOVA · p = 0.2052 (Threshold for significance at 0.025 level.) · Least squares (ls) mean difference: -1.58 · 95% CI -4.37 to 1.22
  • Group 2: REGN2176-3 (3 mg:2 mg) vs Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg · ANCOVA · p = 0.0982 (Threshold for significance at 0.025 level.) · Least squares (ls) mean difference: -1.70 · 95% CI -4.00 to 0.61
SecondaryChange From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT)

CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Microns
Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT)
MicronsGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg
Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT)-131.1 ± 6.88-116.9 ± 4.96-134.4 ± 4.92
SecondaryPercentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT)

CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT)
Percentage of ParticipantsGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg
Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT)35.024.042.1
SecondaryChange From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA)

The anatomical state of the retinal vasculature of the study eye and the fellow eye was evaluated by funduscopic examination, fundus photography and FA to evaluate the total lesion area, CNV area, classic CNV area, and fluorescein leakage. CNV area values measured in square millimeters, each disc area was equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Square Millimeter (mm^2)
Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA)
Square Millimeter (mm^2)Group 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg
Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA)-3.4 ± 0.44-2.0 ± 0.31-3.6 ± 0.31
SecondaryChange From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA)

Total Lesion Size was assessed by Fluorescein Angiography.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mm
Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA)
mmGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg
Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA)-3.1 ± 0.43-2.1 ± 0.31-3.5 ± 0.31
SecondaryPercentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at Week 12 compared with baseline.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)
Percentage of ParticipantsGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg
Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)11.718.521.8
SecondaryPercent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT)

SHM was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT)
Percent changeGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg
Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT)-50.0 ± 5.94-41.9 ± 4.17-48.8 ± 4.14
SecondaryChange From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT)

CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Microns
Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT)
MicronsGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg
Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT)-150.7 ± 7.40-139.6 ± 5.32-160.4 ± 5.29

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 52) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: REGN2176-3 (1 mg:2 mg)3/103 (2.9%)17/103 (16.5%)48/103 (46.6%)
Group 2: REGN2176-3 (3 mg:2 mg)2/106 (1.9%)20/106 (18.9%)50/106 (47.2%)
Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg3/108 (2.8%)23/108 (21.3%)51/108 (47.2%)
Group 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mg1/94 (1.1%)17/94 (18.1%)52/94 (55.3%)
Group 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg)1/94 (1.1%)15/94 (16%)52/94 (55.3%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mgGroup 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mgGroup 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg)
Atrial fibrillationCardiac disorders1/1031/1060/1084/941/94
PneumoniaInfections and infestations1/1031/1060/1083/941/94
FallInjury, poisoning and procedural complications0/1032/1061/1083/941/94
Cardiac failure congestiveCardiac disorders3/1030/1060/1081/940/94
Retinal haemorrhageEye disorders0/1030/1060/1080/942/94
Visual acuity reducedEye disorders2/1031/1060/1080/941/94
UveitisEye disorders1/1032/1060/1081/940/94
SepsisInfections and infestations0/1032/1060/1081/941/94
Femur fractureInjury, poisoning and procedural complications0/1032/1060/1080/941/94
BronchitisInfections and infestations0/1030/1062/1080/940/94
Most frequent other events
Showing 10 of 16
Most frequent other events
EventGroup 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mgGroup 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mgGroup 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg)
Urinary tract infectionInfections and infestations7/1037/1064/1087/9413/94
Conjunctival haemorrhageEye disorders6/1034/1066/10811/949/94
Vitreous floatersEye disorders2/1031/1061/1083/9410/94
Neovascular age-related macular degenerationEye disorders1/10310/1068/1088/945/94
HypertensionVascular disorders6/1034/10610/1082/945/94
NasopharyngitisInfections and infestations3/1036/1069/1085/948/94
Retinal haemorrhageEye disorders6/1038/1063/1085/943/94
Vitreous detachmentEye disorders3/1033/1062/1087/943/94
SinusitisInfections and infestations2/1037/1062/1084/947/94
Eye painEye disorders3/1035/1061/1086/942/94

Baseline characteristics

Baseline population included all randomized participants.

Age, Continuous
Age, Continuous(years)Group 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mgTotal
Mean79.2 ± 8.0178.6 ± 8.7777.7 ± 8.6178.3 ± 8.56
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mgTotal
Female61121135317
Male427967188
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mgTotal
Hispanic or Latino17614
Not Hispanic or Latino102193196491
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mgTotal
American Indian or Alaska Native0011
Asian591024
Native Hawaiian or Other Pacific Islander0000
Black or African American0123
White98189186473
More than one race0112
Unknown or Not Reported0022
Region of Enrollment
Region of Enrollment(Participants)Group 1: REGN2176-3 (1 mg:2 mg)Group 2: REGN2176-3 (3 mg:2 mg)Group 3: Intravitreal Aflibercept Injection (IAI) 2 mgTotal
United States98193194485
Japan57820
08

Study locations

84 sites
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Arcadia, California, United States
  • Beverly Hills, California, United States
  • Irvine, California, United States
  • Mountain View, California, United States
  • Oceanside, California, United States
  • Sacramento, California, United States
  • Santa Ana, California, United States
  • Colorado Springs, Colorado, United States
  • Fort Lauderdale, Florida, United States
  • Fort Myers, Florida, United States
  • Jacksonville, Florida, United States
  • Melbourne, Florida, United States
  • Miami, Florida, United States
  • Plantation, Florida, United States
  • Tampa, Florida, United States
  • Winter Haven, Florida, United States
  • Augusta, Georgia, United States
  • Marietta, Georgia, United States
  • Chicago, Illinois, United States
  • Oak Forest, Illinois, United States
  • Springfield, Illinois, United States
  • Urbana, Illinois, United States
  • Iowa City, Iowa, United States
  • Shawnee Mission, Kansas, United States
  • Lexington, Kentucky, United States
  • Paducah, Kentucky, United States
  • Baltimore, Maryland, United States
  • Towson, Maryland, United States
  • Boston, Massachusetts, United States
  • Jackson, Michigan, United States
  • Southfield, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Florissant, Missouri, United States
  • Lincoln, Nebraska, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Bloomfield, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Albany, New York, United States
  • East Setauket, New York, United States
  • Great Neck, New York, United States
  • New York, New York, United States
  • Orchard Park, New York, United States
  • Rochester, New York, United States
  • Asheville, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Kingston, Pennsylvania, United States
  • Monroeville, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Florence, South Carolina, United States
  • Ladson, South Carolina, United States
  • West Columbia, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Knoxville, Tennessee, United States
  • Memphis, Tennessee, United States
  • Nashville, Tennessee, United States
  • Abilene, Texas, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • McAllen, Texas, United States
  • San Antonio, Texas, United States
  • The Woodlands, Texas, United States
  • Willow Park, Texas, United States
  • Salt Lake City, Utah, United States
  • Burlington, Vermont, United States
  • Fairfax, Virginia, United States
  • Bellevue, Washington, United States
  • Akita, Japan
  • Asahikawa, Japan
  • Chiyoda-ku, Japan
  • Fukushima, Japan
  • Kawasaki, Japan
  • Matsumoto, Japan
  • Nagasaki, Japan
  • Nagoya, Japan
  • Osaka, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2015 to primary completion in Aug 2016, 15 months.

Results were first posted in Oct 2020, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2015
First posted
Apr 16, 2015
StartActual
May 5, 2015
Primary completionActual
Aug 17, 2016
CompletionActual
Apr 3, 2017
Results first posted
Oct 26, 2020
Last update
Oct 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02418754
Responsible party
Sponsor
First posted
Apr 16, 2015
Start date
May 5, 2015
Primary completion
Aug 17, 2016
Completion
Apr 3, 2017
Results posted
Oct 26, 2020
Last update
Oct 26, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion